Company Overview and News

40
Short Sellers Jump on One Solar, One Alt Energy Stock

2018-09-13 247wallst
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on August 31. Of the companies we watch, short interest rose on two of three solar stocks and rose on three of five alternative energy stocks. We’ve added fuel cell maker Bloom Energy to our watch list this week.
SPWR CLNE BE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL

3
Aemetis Has Three Biofuels Segments With Very Different Outlooks

2018-08-28 seekingalpha - 1
Biofuel producer Aemetis has two existing and one planned biofuels segments that have very different outlooks.
AMTX GPRE REGI PEIX

1
REX American Resources: What To Expect From The Q2 Earnings Report

2018-08-27 seekingalpha
U.S. ethanol producer REX American Resources is scheduled to report its Q2 earnings for the period ending July 31 before the market opens this Tuesday.
REX GPRE PEIX

1
Ethanol Headwinds Are Persisting In Q3

2018-08-27 seekingalpha
U.S. ethanol producers have suffered through their lowest summer production margins in three years as the EPA has taken steps to weaken the U.S. biofuel blending mandate.
ANDE REX GPRE PEIX

44
Short Sellers Search for Direction on Solar, Alt Energy Stocks

2018-08-27 247wallst - 4
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on August 15. Of the companies we watch, short interest rose on two of three solar stocks and rose on two of four alternative energy stocks.
SPWR CLNE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL

2
Pacific Ethanol's (PEIX) CEO Neil Koehler on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha - 1
Good day, ladies and gentlemen, and welcome to the Pacific Ethanol’s Second Quarter 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, this conference call is being recorded.
PEIX

1
PEIX / Pacific Ethanol, Inc. FORM 10-Q (Quarterly Report)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
PEIX

2
Merck KGaA (MKGAF) Q2 Earnings Down Y/Y, Sales Flat

2018-08-09 zacks
Merck KGaA is a science and technology company specializing in the fields of healthcare, life science and performance materials. The company's portfolio comprises a wide array of products ranging from innovative pharmaceuticals and biopharmaceuticals to life science tools, specialty chemicals and high-tech materials.
MKGAF MKGAY PEIX OSUR

6
Pacific Ethanol (PEIX) Reports Q2 Loss, Misses Revenue Estimates

2018-08-09 zacks
Pacific Ethanol (PEIX - Free Report) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.
VNOM COLL PEIX AKBA

1
PEIX / Pacific Ethanol, Inc. 8-K (Current Report)

2018-08-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K
PEIX

1
Pacific Ethanol Completes Solar Power Project at Madera Ethanol Plant

2018-08-07 globenewswire
SACRAMENTO, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Pacific Ethanol, Inc. (NASDAQ: PEIX), announced today the completion of a 5-megawatt solar power system at its 40 million gallon capacity per year ethanol plant in Madera, California. The system is online and generating power. Initial operations are at 3.5 megawatts and will increase to 5 megawatts upon completion of PG&E upgrades to the adjacent substation, which are expected in the fourth quarter of 2018.
PEIX

1
What To Watch For From The Andersons In Its Q2 Earnings

2018-08-06 seekingalpha
The company's share price has largely been insulated by this year's poor performance in the ethanol sector by its diversified operating segments.
ANDE GPRE REX PEIX

1
Pacific Ethanol to Release Second Quarter 2018 Results

2018-08-01 globenewswire
SACRAMENTO, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Pacific Ethanol, Inc. (NASDAQ: PEIX), announced it will release its second quarter 2018 financial results after the market closes on Wednesday, August 8, 2018. Management will host a conference call at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time on Thursday, August 9, 2018. Neil Koehler, Chief Executive Officer, and Bryon McGregor, Chief Financial Officer, will deliver prepared remarks via webcast followed by a question and answer session.
PEIX

3
What To Watch For In Pacific Ethanol's Q2 Earnings

2018-07-31 seekingalpha - 2
Pacific Ethanol's share price has struggled mightily since the beginning of 2017 even as the corn price has declined and the gasoline price has increased.
PEIX

4
Ethanol's Post-Pruitt Bump Is Already Over

2018-07-27 seekingalpha - 1
New EPA administrator Andrew Wheeler recently made comments at an EPA event that suggest a reduction to the U.S. biofuel mandate's volumes for 2019 remain in place.
PBF DK CVI HFC REX GPRE CVRR PEIX MPC

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 69423U305